PTGS2 and cancer: CD44 variant isoforms including CD44v9 mitigate ROS [31, 36], which may explain the high level of expression of CD44v9 in addition to S100P and COX-2 predominantly in the tissues of OV-CCA, a cancer driven by inflammation.